Toggle navigation
Home
Search
Services
Blog
Contact
About
Recombinant Human C1 Inhibitor for Treatment of Heredit*
Nuijens, Jan H.
Pharming Technologies, B.V., Leiden, Netherlands
Search grants from Jan Nuijens
Search grants from Pharming Technologies, B.V.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Electric Field-stimulated Protein Mechanics
The VITAL Rhythm Study
Molecular Mechanisms of Adverse Metabolic Events by Asparaginase.
Epididymal PMCA4 Expression Functional Impact and Mechanism of Sperm Uptake
Curricular Enhancement of the Sciences through the Vertical Integration and Interdisciplinary Applications of GCMS
Recently added grants:
'Two year outcomes after dextrose gel prophylaxis for neonatal hypoglycaemia'
Basic and Clinical Studies in Reinforcing Positive Behaviors in Intellectual and Developmental Disabilities
Molecular and Vascular MRI of Placenta Accreta
Applying Diffusion Basis Spectrum Imaging to Characterize Human Placenta Immuno-response during normal term and preterm pregnancies
Molecular Regulation of Atherosclerosis
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Research Project (R01)
Project #
3R01FD003086-01S1
Application #
7675911
Study Section
Special Emphasis Panel (ZFD1-OPD-L (C1))
Program Officer
Ganti, Usha
Project Start
2006-09-20
Project End
2009-08-31
Budget Start
2006-09-20
Budget End
2009-08-31
Support Year
1
Fiscal Year
2008
Total Cost
Indirect Cost
Institution
Name
Pharming Technologies, B.V.
Department
Type
DUNS #
City
Leiden
State
Country
Netherlands
Zip Code
Related projects
NIH 2008
R01 FD
Recombinant Human C1 Inhibitor for Treatment of Heredit*
Nuijens, Jan H. / Pharming Technologies, B.V.
NIH 2006
R01 FD
Recombinant Human C1 Inhibitor for Treatment of Heredit*
Nuijens, Jan H. / Pharming Technologies, B.V.
Comments
Be the first to comment on Jan Nuijens's grant